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Abstract 
Purpose. The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been 
previously studied. This study was aimed to determine the adherence to pegvisomant treatment in acromegaly 
patients in the real-world clinical practice setting in Spain. 
Methods. Multicenter, observational, descriptive, cross-sectional study in patients with acromegaly treated 
with pegvisomant for at least 12 months. Patient adherence was indirectly determined by Batalla and Haynes-
Sackett questionnaires and directly by prescription record review. Additionally, treatment satisfaction was 
assessed by the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) and treatment 
convenience by an ad-hoc Pegvisomant questionnaire. Errors in reconstitution and administration process 
were determined by direct observation. 
Results. 108 patients were included in the analysis. Rates of adherence varied from 60.7 to 92.1% and did not 
correlate with disease control. Older patient age and alternative schedules other than daily pegvisomant 
dosing were associated with lower adherence. Treatment satisfaction and convenience was high, with a mean 
(SD) total SATMED-Q score of 74.6 ± 15.4 over 100 and a total ad-hoc Pegvisomant questionnaire score of 
71.2 ± 15.2 over 100. 34.3% of patients made mistakes during the reconstitution /administration process. 
Conclusions. Patient adherence to pegvisomant was high (60.7–92.1%), but more than a third of the patients 
in the study made mistakes during the administration process, with a potential impact on disease control. 
Besides dosing compliance, correct administration of medication should be carefully assessed in these 
patients. 
Keywords 






Acromegaly, a rare and chronic disease usually caused by a pituitary adenoma, is characterized 
by hyper-secretion of growth hormone (GH) with a consequent increase in insulin-like growth 
factor I (IGF-1). It leads to a multisystem disease associated with multiple comorbidities, 
premature mortality, and physical disfigurement [1]. Acromegaly is equally distributed between 
sexes [2], with an annual incidence rate of 0.2–1.1 cases/100,000 people [3]. Median age at 
diagnosis is 40.5–47 years and it is frequently diagnosed 4.5–5 years after the onset of symptoms 
[2, 3, 4]. Untreated or undertreated acromegaly is associated with a 2–3-fold increased mortality 
and higher risk of suffering from metabolic malfunction and cardiovascular diseases [5]. 
 
Surgery, radiotherapy and pharmacotherapy [6] are the treatment options currently available. 
Pharmacotherapy includes somatostatin analogs (SSA) and pegvisomant (Somavert®), a GH 
receptor antagonist approved in Europe for patients whose disease has not been controlled by 
surgery and/or irradiation and have intolerance or lack of efficacy to SSA [6, 7]. 
 
Pegvisomant improves symptoms and normalizes IGF-1 levels [7, 8]. Pivotal studies in 
patients with acromegaly treated with pegvisomant showed efficacy rates of 90% [8, 9]. However, 
data from observational studies showed that long-term effectiveness in a normal clinical setting 
could be lower (67%) [10, 11], which may be related to an insufficient dose titration, poor patient 
compliance or to inadequate reconstitution and/or administration of treatment [10, 12]. 
 
Treatment adherence decreases in chronic diseases and it is associated with increased 
morbidity and mortality [13, 14] and increased healthcare costs [13, 14, 15]. Patient treatment 
perception is critical for adherence to treatment and thus for achieving optimal treatment effects 
[16, 17, 18]. Adherence seems also to be influenced by patients’ knowledge of the disease and its 
course [12]. Moreover, treatment satisfaction is related to patients’ health-related decisions and 
treatment-related behaviors [19, 20]. Since medical treatment of acromegaly is usually long-term, 
how patients perceive their disease and medical treatment will also affect their compliance. 
Currently, published data regarding treatment patient adherence to or satisfaction with treatment in 
acromegaly are scarce [12, 20]. 
 
Considering the potential patient burden of chronic daily subcutaneous administration of 
pegvisomant, patient adherence may have an impact on effectiveness not previously studied. This 
study was aimed to assess the adherence to pegvisomant in acromegaly patients in a real-world 
clinical practice setting in Spain. Other secondary objectives were to identify potential 
administration errors, describe patient satisfaction with medication, assess the relationship between 
lack of adherence and disease control and identify potential risk factors that predict poor patient 
adherence. 
Materials and methods 
PEGASO study (PEGvisomant Adherence Study—Observational) was an observational, cross-
sectional, multicenter study carried out during endocrinology consultations in acromegaly referral 
hospitals in Spain. The study included adult patients, diagnosed with acromegaly, on pegvisomant 
treatment for at least 12 months, and with complete clinical reports available for this period. 
 
Demographic data, acromegaly clinical history and comorbidities were obtained from clinical 
records. Control of disease according to IGF-1 levels and signs and symptoms of acromegaly 
assessed by patients using the Patient-Assessed Acromegaly Symptom Questionnaire (PASQ) [9] 
were also recorded. IGF-1 level was measured locally and recorded as ≤ or > to upper limit of 
normality (ULN) for patient age and the assessment method used. Patient adherence was indirectly 
determined by two questionnaires (Batalla’s [21, 22] and Haynes-Sackett’s [23]) and a 
prescription record review using hospital or ambulatory drug dispensing registers. Treatment 
satisfaction and self-perception of pegvisomant therapy were assessed with the Treatment 
Satisfaction with Medicines Questionnaire (SATMED-Q) [24] and an ad-hoc Pegvisomant 
questionnaire, respectively. Patients were asked during the study interview to simulate the 
preparation and administration of pegvisomant in the same way as they normally did. Potential 
errors in the process (compared to patient leaflet instructions) were collected by trained healthcare 
staff (Online resource 1). 
 
Batalla questionnaire [21] provides information about the patients’ knowledge of their illness, 
and has been related to patient compliance in many chronic diseases [21, 22]. Patients were 
considered non-compliant when they answered incorrectly one of the three following questions: 
“Is acromegaly a lifelong disease?; Is it possible to control this disease with medication?; Can 
you mention two or more organs that may become damaged by non-controlled acromegaly?” 
 
In the Haynes-Sackett questionnaire the patient states his/her adherence to treatment [23]. The 
assessment of adherence was introduced by the following sentence: “Most of the patients have 
difficulties in administering all their prescribed doses”, then the patient was asked “do you have 
any difficulty in administering the medication?”. Afterwards, the patient was asked about the 
number of injections administered in the past month with the following question: “in the last 28 
days, how many injections of pegvisomant have you failed to inject?”. A modified version of the 
Haynes-Sackett test that takes into account biochemical control of the disease (IGF-1 level) was 
used to better discriminate non-compliant patients (Online resource 2), as was described before 
[23, 25]. A patient was considered non-adherent to treatment if he/she reported having difficulties 
in administering the medication or if he/she did not report having any difficulty in administering 
the medication, but his/her acromegaly was not controlled (IGF-1 > ULN) and he/she reported 
administering less than 80% of pegvisomant injections during the last 4 weeks (Online resource 2). 
 
SATMED-Q questionnaire [24] assesses medical treatment satisfaction in 6 dimensions: 
undesirable side effects (items 1,2,3); treatment effectiveness (items 4,5,6); convenience of use 
(items 7,8,9); impact on daily living/activities (items 10,11,12); medical care (items 13,14) and 
global satisfaction (items 15,16,17). Total score was standardized to range from 0 (not satisfied) to 
100 (completely satisfied). 
 
The ad-hoc Pegvisomant questionnaire is composed of 9 items that address different aspects 
regarding the perceived convenience of pegvisomant treatment: I have a clear understanding on 
how to prepare and administer Somavert; I consider the preparation of treatment an easy 
procedure; I consider the administration of Somavert a simple procedure; I consider the 
administration of Somavert a rapid procedure; I used to rotate the injection site daily; Travelling 
with my medication is easy; I do not feel anxious about injections; Getting needles is easy; I find it 
easy to dispose of syringes and needles after their use. Items are scored on a 5-point Likert scale 
(no = 0, little = 1, somewhat = 2, quite = 3, yes, very = 4). Total score was standardized to range 
from 0 (not satisfied) to 100 (completely satisfied). 
 
PASQ questionnaire [9] is a disease-specific questionnaire for assessing symptoms. It is 
composed of 6 items scoring 0–8 that evaluate acromegaly symptoms such as headache, excessive 
sweating, joint pain, fatigue, soft tissue swelling, and numbness or tingling of extremities. The 
maximum score of these six questions is 48 and indicates severe symptoms, with lower scores 
reflecting milder symptoms. In addition, a seventh item addresses overall health status scoring 
from 0 (very good) to 10 (very bad). Total score was standardized to range from 0 (no symptoms) 
to 100 (severe symptoms). 
  
Statistical methodology 
A descriptive statistical analysis of all the variables was performed, including central tendency 
and dispersion measures for continuous variables, and absolute and relative frequencies for 
categorical variables. Student’s t-test was used to compare quantitative variables and Pearson’s 
Chi square or Fisher’s exact tests for qualitative variables. Tests were two-tailed with a 
significance level of 5%. Data were analyzed using SPSS V19.0 statistical software. Univariate 
and multivariate logistic regression analysis were performed between adherence (according to 
Batalla or Haynes-Sackett questionnaire) and baseline variables (age, time since diagnosis, time 
with symptoms before diagnosis, concomitant treatments, sex, previous treatments, disease control 
by IGF-1 levels, daily administration). For the multivariate analysis, variables entering in the 
model were selected by backward stepwise elimination. 
 
The inter-rater agreement between adherence measured by medication count and by the 
questionnaires used in the study (Batalla’s and Hynes Sacket’s) was analyzed using Kappa 
concordance index. 
Results 
A total of 113 patients were included, 108 of whom were considered evaluable. Five patients 
were not included in the analysis for the following reasons: 1 patient with no informed consent 
available, 4 patients with incomplete data. Table 1 summarizes patients’ demographic and clinical 
characteristics. Most subjects were women (60.2%) with a mean (SD) age of 55.1 (14.5) years and 
a mean (SD) of disease duration of 11.3 (6.9) years. The mean (SD) time with symptoms before 
diagnosis of acromegaly was 4.4 (3.8) years. The majority of patients (92.6%) suffered from some 
concomitant disease, 52% presented at least 4 comorbid conditions. Nearly all patients (99.1%) 
received concomitant medication. Previously to Pegvisomant treatment, most of patients had 
undergone pituitary surgery (85.0%) and received SSA treatment (94.4%). The main reason for 
pegvisomant treatment initiation was resistance to SSA (82.4%). Mean (SD) duration of 
pegvisomant treatment was 5.9 (3.5) years and the mean (SD) daily dose was 15.2 (9.8) mg 
(18.7 mg/day and 13.8 mg/day in non-controlled patients and controlled patients according to IGF-
1 levels). 60.2% of patients administered pegvisomant daily while 39.8% of patients followed 
alternative dosing schedules other than once daily dosing (Online resource 3). 
  
Table 1 Demographic and clinical characteristics of the study population 
  Total N (108) 
  
Women, n (%) 65 (60.2) 
Age, mean (SD), yr 55.1 (14.5) 
Time since diagnosis, mean (SD), yr 11.3 (6.9) 
Time with symptoms before diagnosis, mean (SD), yr 4.4 (3.8) 
Co-morbidities, n (%) 100 (92.6) 
 Endocrine/metabolic disease 82 (82.0) 
 Musculoskeletal disease 65 (65.0) 
 Cardiovascular disease 58 (58.0) 
 Visual field defects 26 (26.0) 
 Respiratory disease 22 (22.0) 
 Digestive and liver disease 20 (20.0) 
Prior therapies, n (%) 
 Surgery 91 (85.0) 
 Radiotherapy 47 (43.9) 
 Somatostatin analogs 101 (94.4) 
 Cabergoline 44 (41.1) 
Controlled acromegaly (IGF-1 < ULN), n (%) 78 (72.2) 
PASQ, mean (SD) 
 Total score (0–48) 17.8 (12.1) 
 Overall health status score (0–10) 4.4 (2.6) 
  
 
IGF-1 insulin-like growth factor I, ULN Upper limit normal, PASQ Patient-
Assessed Acromegaly Symptom Questionnaire 
Overall, 72.2% of patients presented controlled acromegaly (IGF-1 < ULN) with a moderately 
good control of symptoms according to PASQ values (Table 1). 
 
Rate of adherence to pegvisomant was 90.6%, as measured by Haynes-Sackett test, 60.7% by 
Batalla test and 92.1% by medication count, the last being available in 38 patients only (Fig. 1). 
According to researchers’ subjective opinion, 94.4% of patients were adherent to treatment. 
Adherent and non-adherent patients did not show significant differences regarding disease control 
for any of the adherence measurement tools (data not shown). The most frequent reason for poor 
adherence stated by patients were travelling (12.0%), memory-related reasons (8.3%) and 





Fig. 1 Rate of patient adherence to pegvisomant treatment assessed by different measuring tools; Proportion and number of 
adherent (dark grey) and non-adherent (light grey) patients according to Prescription Record Review, Haynes-Sackett 




Fig. 2  Reasons of poor adherence to pegvisomant; Proportion of patients that reported the following statements as reasons 
for poor adherence. “Other” reasons included forgetfulness (n = 4), patient decision (n = 1), forgetfulness due to non-daily 
administration (n = 1), and none of the above (n = 4). In all, 9 (8.3%) patients were poorly adherent to treatment due to 
memory-related reasons 
Patients stated a high satisfaction with the treatment as measured by SATMED-Q 
questionnaire [mean (SD) total score 74.6 (15.4)] (Fig. 3). Lower satisfaction sub-scores were 
obtained on convenience of use and impact on daily living/activities dimensions, whereas higher 
patient satisfaction sub-scores were obtained on medical care, global satisfaction and undesirable 





Fig. 3 Patients’ satisfaction with pegvisomant treatment assessed by SATMED-Q; Mean (SD) Total SATMED-Q score and 
6 dimension sub-scores relative to the maximal score (100) 
Overall, perceived convenience of pegvisomant therapy measured by the ad-hoc Pegvisomant 
questionnaire was high [mean (SD) total score 71.2 (15.2)]. Nearly all patients (98.0%) had a clear 
or very clear understanding of how to prepare and administer pegvisomant and main concerns 




Fig. 4 Patients perceived convenience of pegvisomant treatment assessed by an ad-hoc Pegvisomant questionnaire; Degree 
of agreement (% of patients) with nine convenience-related statements and 6 dimension sub-scores 
 
  
According to the Haynes-Sackett’s questionnaire the proportion of adherent patients was 
higher when daily dosing schedules were used [61 (95.3%) vs. 35 (83.3%) p = 0.048]. Univariate 
logistic regression analysis also showed this correlation [OR (95% CI)= 4.067 (0.988–6.739)], 
although not significantly (p = 0.052). Non-adherent patients expressed significantly lower 
satisfaction regarding convenience of use dimension of SATMED-Q compared to adherent patients 
(42.5 ± 30.3 vs. 64.9 ± 26.3; p = 0.013). Non-adherent patients showed a significantly lower total 
score on the ad-hoc Pegvisomant questionnaire (72.3 ± 15.3 vs. 60.2 ± 10.9; p = 0.023), particularly 
in the dimensions I consider the preparation of treatment an easy procedure (p = 0.003) and I 
consider the administration of pegvisomant a rapid procedure (p = 0.007). 
 
According to Batalla questionnaire, the only factor associated with low adherence was patient 
age. Non-adherent patients were older than adherent patients (59.0 ± 13.2 vs. 52.8 ± 15.0; 
p = 0.032). Univariate logistic regression analysis confirmed this correlation [OR (95% CI)= 0.970 
(0.943–0.998), p < 0.05]. Multivariate logistic regression analysis did not provide any valid models 
between adherence (with either method) and baseline variables. 
 
Adherence rate measured by Haynes-Sackett test showed a significant correlation with 
adherence rate measured by medication count (p < 0.001). Inter-rater agreement between both 
methods was moderate (κ value = 0.55). 100% of non-adherent patients by medication count were 
also non-adherent patients by Haynes-Sackett test and 87.9% of adherent patients by medication 
count were also adherent patients by Haynes-Sackett test. No correlation or concordance was 
observed between Batalla test and medication count. 
 
Thirty-five (34.3%) patients made at least one mistake at some phase of the 
reconstitution/administration procedure (Fig. 5). Among mixing mistakes, 11 (10.8%) patients 
made a mistake in steps 4–6, (diluent collection, injection of diluent into pegvisomant vial, mixing, 
see Online Resource 1) defined as “critical steps”. Among administration errors, 5 (4.9%) patients 
made mistakes in step 1 (choice of injection site) and 8 (7.8%) in steps 3–4 (needle introduction 
and injection), defined as “critical steps”. The proportion of patients with controlled acromegaly 
(IGF-1 < ULN) was numerically lower but not significantly in the group of patients who made 
mistakes (62.9% vs. 74.6%; p = 0.216). Patients who did not mix the treatment correctly presented 





Fig. 5 Mistakes in reconstitution/administration procedure; Number and proportion of patients that made at least one 




This study is the first to measure pegvisomant adherence in acromegaly patients in real-world 
clinical practice. 
 
Currently, there is not a single gold-standard method to measure adherence, so a multi-method 
approach is recommended to study adherence behavior. Patient-reported questionnaires are widely 
used and there is a variety available, but none has been validated to measure adherence in patients 
with acromegaly. Here, we used two patient questionnaires, Haynes-Sackett’s [25] and Batalla’s 
[21], both validated in Spanish patients. Pegvisomant adherence rates varied from 90.6% by 
Haynes-Sackett modified test to 60.7% by Batalla test. While, healthcare providers rated 
adherence higher (94.4%) than any of the measurement tools used [26]. Batalla questionnaire has 
an adequate sensitivity but tends to underestimate adherence, whereas Haynes-Sackett 
questionnaire has a good specificity and tends to overestimate adherence. The combined use of 
both questionnaires may complement each other and give an adequate range of patient adherence 
rate to pegvisomant treatment. Prescription record review or medication count is an easy, rapid and 
quantitative tool to measure adherence. In this study, it was intended to be compared as a gold-
standard to patients’ questionnaires. This method showed an adherence rate similar to Haynes-
Sackett test (92.1%). Moreover, there was a statistically significant correlation between adherence 
rate measured by medication count and Haynes-Sackett test and a moderate concordance between 
both methods. This correlation and concordance was not observed with Batalla test. Therefore, 
Haynes-Sackett test may be a more appropriate patient survey to assess adherence in this study. 
However, this results should be interpreted with caution, given the low number of patients with 
medication count data available (n = 38). Similarly to our results, adherence to medications among 
other chronic diseases also varies widely, with estimates ranging from 36%-94% [27, 28]. 
 
In acromegaly, drug adherence is essential to maintain normalized IGF-1 levels and to reduce 
morbidity and mortality. In a recent study on 120 long-standing acromegaly patients, non-
compliance was the reason for failure to achieve disease control in 20.6% of patients [12]. In the 
present study, however, adherence did not correlate with disease control, which may be due to the 
higher rate of adherence assessed by patients’ questionnaires. The present study showed that after 
a mean of 5.9 years on pegvisomant treatment, 72.2% of patients had normal IGF-1 levels using a 
mean dose of 15.2 mg/day. This results are comparable to those reported in the global 
ACROSTUDY [29] (63.2% IGF-1 normalized patients, 3.7 years of follow-up, mean daily dose of 
18.0 mg) and in the Spanish ACROSTUDY subpopulation [11] (67.9% IGF-1 normalized patients, 
6.7 years of follow-up, mean daily dose of 15.5 mg). 
 
Correct reconstitution/administration of treatment is part of treatment adherence and may have 
an impact on effectiveness [30]. In this study nearly all patients (98%) stated understanding how to 
prepare and administer the injections according to the ad-hoc Pegvisomant questionnaire. 
However, more than a third of patients (34.3%) made mistakes during the 
reconstitution/administration procedure. These mistakes may have an impact on disease control, 
and, indeed, patients who mixed the treatment correctly presented a significantly better control of 
symptoms as measured by PASQ than those that did not. Moreover, the proportion of patients that 
did not make any mistakes during the procedure was notably higher in those with IGF-1 controlled 
levels (non-significant difference). This analysis did not take into account differences between 
critical (i.e. vial mixing, injection) and non-critical (i.e. hand-washing, needle disposal) steps in 
the process in terms of effectiveness impact. Mistakes during those critical steps may have a 
higher potential influence on disease control. 
 
Poor adherence, including incorrect reconstitution/administration of pegvisomant may partially 
explain the discrepancies observed in disease control between clinical trials [8] and real-world 
clinical studies [10]. However, there may be other causes such us insufficient dose escalation. A 
recent survey based on the German Acromegaly registry database of 1755 patients showed that 
one of the most common reasons for long-standing active disease, together with non-compliance, 
was the patient’s refusal to intensify or escalate [12] the treatment. Moreover, Ramos-Levi et al. 
[31] recently published a rate of 89.5% of patients with normal IGF-1 levels after 6.8 years 
receiving a mean dose of pegvisomant higher than the observed in our study (19 ± 8 mg/day during 
the first 5 years of follow up and 20 ± 9 mg/day thereafter). 
 
Treatment satisfaction is associated with treatment-related behaviors such as adherence [17, 
20] but data in acromegaly are scarce. A recent survey conducted in 195 patients to assess the 
burden of lifelong injections of somatostatin analogs showed that, despite the daily life impact of 
injections, patients were satisfied with the treatment [32]. Here, patients stated a high global 
satisfaction with pegvisomant treatment according to the SATMED-Q questionnaire (score 
74.6/100). Perceived convenience of pegvisomant as measured by the ad-hoc Pegvisomant 
questionnaire was also high (score 71.2/100) although there is room for improvement. Travelling 
with medication, however, seems to be a main concern for patients since it was one of the 
statements worst rated by the Pegvisomant ad-hoc questionnaire and it was also one of the main 
reasons for non-adherence. Traveling with pegvisomant requires maintaining the cold chain during 
the trip and this may be one of the reasons for skipping injections. 
 
Identifying factors associated with poor compliance is useful for implementing strategies 
targeted to increase adherence. However, there are no consistent characteristics that can reliably 
predict adherence [15]. In this study, older patient age is associated with low adherence according 
to Batalla test. Patients’ perception of their medical treatment also affects their adherence since, 
non-adherent patients according to the Haynes-Sackett test, expressed significantly lower 
satisfaction regarding convenience of medication by SATMED-Q and worse self-perception of 
pegvisomant therapy by the ad-hoc Pegvisomant questionnaire. Daily administration of 
pegvisomant was also associated with higher adherence according to the Haynes-Sackett test. 
Alternative dosing schedules other than daily dosing, i.e. several administrations per week, add 
complexity to the treatment regimen and doses may be more easily forgotten than routinely daily 
dose administration. In fact, complexity of the treatment is recognized as a predictor of adherence 
[15]. Other causes may underlie, and we cannot rule out that non-daily regimens were prescribed 
more frequently to non-adherent perceived patients, although this possibility seems unlikely given 
the high rate of adherence perceived by researchers (94.4%). 
 
Taken together, there may be some modifiable factors that influence pegvisomant adherence, 
such as ease of treatment administration and travelling, dosing schedule, dosing recall, and patient 
training on pegvisomant reconstitution/administration. The new pegvisomant water-filled injection 
device may help to overcome convenience and ease of administration problems. Working on 
training the patients in reconstruction and administration can lead to a better adherence and to an 
enhancement of the effectiveness of pegvisomant. 
 
Some limitations stemming from the cross-sectional nature of this study must be considered, 
since treatment adherence should be monitored longitudinally to be more reliable. Patients willing 
to participate in a study may be more adherent to treatment than patients that declined to 
participate. Also, inclusion criteria required patients to be on pegvisomant treatment for at least 12 
months, and therefore, those that abandoned treatment earlier for reasons related to or with an 
impact on adherence were not included in the study. In addition, indirect methods to assess 
adherence to treatment are simple, non-expensive and useful tools in normal clinical practice, but 
are less objective and tend to over-estimate patient adherence compared to direct methods. The 
questionnaires used in this study, although validated and used in other diseases, have inherent 
limitations: (i) The relationship between disease awareness and adherence in Batalla test may not 
be real in all patients; (ii) the modified Haynes-Sackett questionnaire used in this study includes 
IGF-1 control in its definition of adherence, which may bias the correlation between adherence and 
disease control. Since we did not find any significant differences in IGF-1 control in adherent vs. 
non-adherent patients (data not shown), we assumed that the impact of this bias is low. IGF-1 was 
not measured centrally, but assessed locally whether patient showed IGF-1 levels ≤ or > to ULN 
for patient age and method used.  
In conclusion, patient adherence to pegvisomant seems to be high (60.7–92.1%) in this real-
world clinical setting, and is consistent with the high treatment satisfaction reported. More than a 
third of patients, however, made mistakes during the administration procedure, with a potential 
impact on disease control. Correct administration of medication is part of patient adherence to 
treatment and, therefore, effective training by the clinician is essential. Adherence should be 
monitored as well as dosing compliance in order to improve the effectiveness of pegvisomant in 
real-world clinical practice. 
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